Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody

Research output: Contribution to journalArticle

Standard

Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody. / D'huyvetter, Matthias; Vincke, Cécile; Xavier, Catarina; Aerts, An; Impens, Nathalie; Baatout, Sarah; De Raeve, Hendrik; Muyldermans, Serge; Caveliers, Vicky; Devoogdt, Nick; Lahoutte, Tony.

In: Theranostics, Vol. 4, No. 7, 04.2014, p. 708-720.

Research output: Contribution to journalArticle

Harvard

D'huyvetter, M, Vincke, C, Xavier, C, Aerts, A, Impens, N, Baatout, S, De Raeve, H, Muyldermans, S, Caveliers, V, Devoogdt, N & Lahoutte, T 2014, 'Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody', Theranostics, vol. 4, no. 7, pp. 708-720. https://doi.org/10.7150/thno.8156

Author

D'huyvetter, Matthias ; Vincke, Cécile ; Xavier, Catarina ; Aerts, An ; Impens, Nathalie ; Baatout, Sarah ; De Raeve, Hendrik ; Muyldermans, Serge ; Caveliers, Vicky ; Devoogdt, Nick ; Lahoutte, Tony. / Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody. In: Theranostics. 2014 ; Vol. 4, No. 7. pp. 708-720.

Bibtex - Download

@article{4d757670b32b4e0a8f66bd0111994eff,
title = "Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody",
abstract = "RIT (Radioimmunotherapy) has become an attractive strategy in cancer treatment, but still faces important drawbacks due to poor tumor penetration and undesirable pharmacokinetics of the targeting vehicles. Smaller radiolabeled antibody fragments and peptides feature highly specific target accumulation, resulting in low accumulation in healthy tissue, except for the kidneys. Nanobodies are the smallest (MW",
keywords = "HER2, nanobody, targeted radionuclide therapy, 177-Lutetium",
author = "Matthias D'huyvetter and C{\'e}cile Vincke and Catarina Xavier and An Aerts and Nathalie Impens and Sarah Baatout and {De Raeve}, Hendrik and Serge Muyldermans and Vicky Caveliers and Nick Devoogdt and Tony Lahoutte",
note = "Score = 10",
year = "2014",
month = "4",
doi = "10.7150/thno.8156",
language = "English",
volume = "4",
pages = "708--720",
journal = "Theranostics",
issn = "1838-7640",
publisher = "Ivyspring International Publisher",
number = "7",

}

RIS - Download

TY - JOUR

T1 - Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody

AU - D'huyvetter, Matthias

AU - Vincke, Cécile

AU - Xavier, Catarina

AU - Aerts, An

AU - Impens, Nathalie

AU - Baatout, Sarah

AU - De Raeve, Hendrik

AU - Muyldermans, Serge

AU - Caveliers, Vicky

AU - Devoogdt, Nick

AU - Lahoutte, Tony

N1 - Score = 10

PY - 2014/4

Y1 - 2014/4

N2 - RIT (Radioimmunotherapy) has become an attractive strategy in cancer treatment, but still faces important drawbacks due to poor tumor penetration and undesirable pharmacokinetics of the targeting vehicles. Smaller radiolabeled antibody fragments and peptides feature highly specific target accumulation, resulting in low accumulation in healthy tissue, except for the kidneys. Nanobodies are the smallest (MW

AB - RIT (Radioimmunotherapy) has become an attractive strategy in cancer treatment, but still faces important drawbacks due to poor tumor penetration and undesirable pharmacokinetics of the targeting vehicles. Smaller radiolabeled antibody fragments and peptides feature highly specific target accumulation, resulting in low accumulation in healthy tissue, except for the kidneys. Nanobodies are the smallest (MW

KW - HER2

KW - nanobody

KW - targeted radionuclide therapy

KW - 177-Lutetium

UR - http://ecm.sckcen.be/OTCS/llisapi.dll/open/ezp_134992

UR - http://knowledgecentre.sckcen.be/so2/bibref/11432

U2 - 10.7150/thno.8156

DO - 10.7150/thno.8156

M3 - Article

VL - 4

SP - 708

EP - 720

JO - Theranostics

JF - Theranostics

SN - 1838-7640

IS - 7

ER -

ID: 192824